Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease

Panagiotis Alexopoulos, Laura Kriett, Bernhard Haller, Elisabeth Klupp, Katherine Gray, Timo Grimmer, Nikolaos Laskaris, Stefan Förster, Robert Perneczky, Alexander Kurz, Alexander Drzezga, Andreas Fellgiebel, Igor Yakushev

Research output: Contribution to journalArticlepeer-review

52 Scopus citations


New diagnostic criteria for Alzheimer's disease (AD) treat different biomarkers of neuronal injury as equivalent. Here, we quantified the degree of agreement between hippocampal volume on structural magnetic resonance imaging, regional glucose metabolism on positron emission tomography, and levels of phosphorylated tau in cerebrospinal fluid (CSF) in 585 subjects from all phases of the AD Neuroimaging Initiative. The overall chance-corrected agreement was poor (Cohen κ, 0.24-0.34), in accord with a high rate of conflicting findings (26%-41%). Neither diagnosis nor APOE ε4 status significantly influenced the distribution of agreement between the biomarkers. The degree of agreement tended to be higher in individuals with abnormal versus normal CSF β-amyloid (Aβ1-42) levels. Prospective diagnostic criteria for AD should address the relative importance of markers of neuronal injury and elaborate a way of dealing with conflicting biomarker findings.

Original languageEnglish
Pages (from-to)684-689
Number of pages6
JournalAlzheimer's and Dementia
Issue number6
StatePublished - 1 Nov 2014


  • Agreement
  • Dementia
  • Diagnostic criteria
  • Hippocampal atrophy
  • Tau


Dive into the research topics of 'Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease'. Together they form a unique fingerprint.

Cite this